Abstract
The Peanut Oral Immunotherapy in Children (IMPACT) trial, a randomized, double-blinded, placebo-controlled study achieved the primary endpoints of desensitisation (D+) in 71% or desensitization and remission (D+R+) in 21% of children treated with peanut oral immunotherapy (POIT). Variance in the gut microbiome relates to allergy and asthma status in childhood. We sought to identify functional and metabolic features of the gut microbiome that relate to the primary clinical endpoints in the IMPACT trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
